Opening Recap
Market Pulse: Retail and biotech headlines rip through early trading after Costco’s earnings beat and Crinetics’ FDA green light set a positive tone, balancing a cautious undertow from healthcare policy chatter.
Key Movers: Costco flexed its pricing power with better-than-expected results, Crinetics caught eyes with PALSONIFY™ approval, and JPMorgan’s shortlist of short-squeeze candidates stirred trader excitement.
Macro & Politics: The 25th anniversary of RU-486 brings reproductive-health debates back to the forefront—any new legislative skirmish could unsettle healthcare shares.
What’s Next: Watch for early signals from earnings season rollouts and any statehouse moves on women’s health that might sway sector rotations.
Market Commentary
Everyone’s missing how quickly sector rotation could stall if adoption curves for PALSONIFY™ hit a regulatory snag—Crinetics may have FDA backing, but real-world rollout can get damn messy when insurers push back on pricing.
Linking the RU-486 retrospectives from Ms. Magazine to JPMorgan’s squeeze pick-list shows a single narrative: politics and social debates are now as tradable as short interest. Traders chasing volatility need to factor in political catalysts just as much as balance-sheet beats.
If you’re loading up on retail stalwarts and biotech speculative plays, tighten your risk controls. Keep stops tight and follow the catalysts—earnings surprises and policy shifts will be your best signals for entry and exit.
📈 Breaking Financial News
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 trials where PALSONIFY was well tolerated and resulted in rapid efficacy.
Crinetics announces FDA approval of PALSONIFY
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corporates up to date.
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
Palsonify is approved by the U.S. FDA to treat adults with acromegaly……
Costco’s Earnings Beat Estimates on Steady Consumer Demand
Costco Wholesale Corp. reported quarterly profit that was better than expectations, a sign that spending remains healthy as shoppers prioritize essentials and seek value.
JPMorgan flags 3 stocks with the ingredients for a short squeeze
Analysts at the bank named three stocks with high demand from retail investors and elevated short interest from institutions.
Is This the End of Tesla?
The media says Tesla is on the ropes, and the “woke mob” is attacking. But they're missing the big picture. A silent partner is powering Elon Musk's $9 trillion comeback. This is your chance to profit while they're distracted.
🔍 Market Analysis & Insights
Infosys, Wipro ADRs fall over 2% despite Accenture's upbeat FY25 revenue, EPS
Infosys and Wipro ADRs slipped after Accenture’s strong Q4 earnings beat estimates, with revenue rising 7% and AI-driven bookings boosting outlook. Despite robust growth, Accenture shares dipped 1.2%, sparking sentiment shifts across global IT stocks.
Ulta Beauty upgraded to Buy at Argus following another earnings beat
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corporates informed.
Best Fat Burner for Men- Effective Men’s Fat Burning Supplements- Wolfsan Brand launch 2025
In 2025, Wolfson Brands has unveiled an advanced line of Best fat-burning supplements for man designed to align with the evolving needs of modern lifestyles. Today, fat management is far from a one-size-fits-all challenge.
Twenty-Five Years of RU-486: How Activists Brought the Abortion Pill to America and Changed Reproductive Health Forever
At the urging of antiabortion advocates and politicians, and based on a flawed and biased report put out by an antiabortion group, the Trump administration announced the launch of a new review of mifepristone, despite 100 peer-reviewed scientific studies proving safety.
Pain Management Drugs Market Size Worth USD 125.68 Billion by 2034 Driven by Aging Population and Rising Chronic Pain Cases
According to Precedence Research, the global pain management drugs market size will grow from USD 87.19 billion in 2025 to nearly USD 125.68 billion by 2034, with a CAGR of 4.10% from 2025 to 2034. The market is set for steady growth, fueled by rising demand.
Stocks DO Move Over the Weekend – Here's PROOF
The mainstream media wants you to believe stocks don't move when the market is closed. But that's a LIE. This millionaire trader has been quietly BANKING thousands every weekend, thanks to a little-known loophole that's hidden from most investors.
💰 Investment Opportunities
Oracle initiated, Ulta Beauty upgraded: Wall Street's top analyst calls
Oracle initiated, Ulta Beauty upgraded: Wall Street's top analyst calls
PROLLENIUM® Named Industry Partner of the Year at Aesthetic Next 2025
TORONTO — PROLLENIUM®, a pioneer in regenerative and medical aesthetics, has been recognized as the Industry Partner of the Year at the Aesthetic Next 2025 conference. The award acknowledges PROLLENIUM®’s unwavering commitment to innovation, education, and collaboration.
UniQure: How QURE Stock Rises 10x To $500?
Even after a remarkable 3x surge from $14 to $48 in a single day, QURE stock appears to have additional upside. We explore these drivers in detail below.
These 13 stocks in a small corner of the market should be on investor radars as earnings season nears
Small- to-mid-cap industrial stocks are heavily discounted and could outperform in the coming earnings season, UBS said.
Press release: Sequana Medical announces H1 2025 results and provides business update
Sequana Medical announces H1 2025 results and provides business update alfapump® US commercialisation underway; Strengthened US reimbursement with…
They're Trying to Cancel Elon Musk, But You Can Profit
The woke mob is targeting Tesla, but savvy investors see a hidden opportunity. A tiny, little-known company is supplying the key technology for Musk's $9 trillion AI revolution. Get in before the mainstream media catches on.